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INTRODUCTION
Male breast cancer (MBC) is one of the rarest cancers 
in men [1]. Even though its incidence is slowly rising [2], in 
Western countries only 0.5–1% of all breast cancers (BC) 
are diagnosed in men [1]. Its incidence rates rise linearly 
with age [1]. Risk factors include a number of diseases 
characterized by an abnormal estrogen-to-androgen ratio, 
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ABSTRACT
Male breast cancer (MBC) is a rare disease and its biology is poorly understood. 
Deregulated Hippo pathway promotes oncogenic functions in female breast cancer. 
We herein investigated the expression of the Hippo transducers TAZ/YAP and their 
target CTGF in MBC. Tissue microarrays containing samples from 255 MBC patients 
were immunostained for TAZ, YAP and CTGF. One hundred and twenty-nine patients 
were considered eligible. The Pearson’s Chi-squared test of independence was used 
to test the association between categorical variables. The correlation between TAZ, 
YAP and CTGF was assessed with the Pearson's correlation coefficient. The Kaplan-
Meier method and the log-rank test were used for estimating and comparing survival 
curves. Cox proportional regression models were built to identify variables impacting 
overall survival. Statistical tests were two-sided. Tumors were considered to harbor 
active TAZ/YAP-driven gene transcription when they co-expressed TAZ, or YAP, 
and CTGF. Patients whose tumors had the TAZ/CTGF and YAP/CTGF phenotypes 
experienced shorter overall survival compared with their negative counterparts (log 
rank p = 0.036 for both). TAZ/CTGF and YAP/CTGF tumors were associated with 
decreased survival in patients with invasive ductal carcinomas, G3 tumors, hormone 
receptor-positive tumors, and tumors with elevated Ki-67. Multivariate analyses 
confirmed that the TAZ/CTGF and YAP/CTGF phenotypes are independent predictors 
of survival (HR 2.03, 95% CI: 1.06–3.90, p = 0.033; and HR 2.00, 95% CI: 1.04–3.84,  
p = 0.037 respectively). Comparable results were obtained when excluding uncommon 
histotypes (TAZ/CTGF: HR 2.34, 95% CI: 1.16–4.73, p = 0.018. YAP/CTGF: HR 2.36, 
95% CI: 1.17–4.77, p = 0.017). Overall, the TAZ/YAP-driven oncogenic program may 
be active in MBC, conferring poorer survival.
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such as obesity, liver diseases and Klinefelter’s syndrome 
[3]. Germ-line mutations in BRCA1 and BRCA2 were also 
associated with MBC [4, 5].  
MBC is a hormone-driven tumor and steroid 
receptors, namely the estrogen receptor (ER), progesterone 
receptor (PgR) and androgen receptor (AR) are often 
expressed [6, 7]. Consistently, hormonal therapies are 
central in the medical management of these patients, 
albeit studies reported so far described retrospective, 
small-sized case series [8–14]. Despite the apparent 
similarities between MBC and post-menopausal female 
breast cancer (FBC) [6], some studies highlighted the 
existence of gender-related molecular differences at the 
genomic [15–17], transcriptome [18, 19], and microRNA 
levels [20]. Nevertheless, characterization efforts of 
MBC are still in their infancy, and the complex molecular 
taxonomy of FBC needs to be carefully considered as a 
potential confounding factor in these comparisons. Overall, 
the nature of deregulated pathway nodes fuelling MBC 
remains largely elusive.
In FBC, overwhelming preclinical evidence showed 
that altered Hippo pathway feeds multiple oncogenic 
functions [21]. The Hippo signaling was originally found 
to be crucial during embryonic development [22]. In 
transgenic animal models its perturbation resulted in 
increased cell proliferation, decreased cell death, altered 
stem cell function and tumorigenesis [23–28]. Mammary 
gland defects were also observed upon manipulation of key 
pathway components [29–31]. 
Functionally, Hippo is composed by a regulatory 
module and a transcriptional module [32]. The first 
encompasses the kinases sterile 20-like kinase 1 and 2 
(MST1/2) and large tumor suppressor 1 and 2 (LATS1/2), 
which require the adaptor proteins Salvador homologue 1 
(SAV1), MOB kinase activator 1A and 1B (MOB1A/1B). 
The activation of the signaling cascade culminates in 
an inhibitory phosphorylation of two closely related 
oncoproteins: the transcriptional co-activator with PDZ-
binding motif (TAZ) and the Yes-associated protein (YAP). 
When this occurs, TAZ/YAP are retained in the cytoplasm 
and/or excluded from the nucleus, and eventually undergo 
proteasomal degradation [22]. Defective activation of the 
regulatory module, or activation of other mechanisms that 
can directly tune TAZ/YAP, promotes the accumulation of 
Hippo transducers into the nucleus. Here, TEA domain-
containing sequence-specific transcription factors (TEADs) 
serve as DNA-binding platforms for TAZ/YAP, mediating 
the transcription of target genes (e.g. CTGF, AXL CYR61, 
and ANKRD1) [22]. Thus, Hippo is a tumor-suppressor 
pathway essential for restraining the oncogenic functions 
elicited by TAZ/YAP. 
In FBC, TAZ/YAP activation was tied to the 
retention/acquisition of cancer stem cell (CSCs) features 
[33, 34]. We and others demonstrated that TAZ sustains 
self-renewal, tumor-forming ability, chemoresistance and 
metastatic spread of breast CSC (BCSCs) [33, 34]. Our 
group has recently promoted translational studies aimed 
at characterizing this emerging BCSC pathway in cancer 
patients, with the goal of identifying potential prognostic 
and predictive biomarkers. Results from exploratory 
analyses in FBC patients provided the first clues that 
the expression of Hippo transducers may confer poorer 
clinical outcomes [35, 36]. 
Within the framework of an Italy-UK 
collaboration striving to provide novel molecular and clinical 
information on MBC, we herein investigated TAZ/YAP and 
their target CTGF in a large cohort of patients. Our goals 
included the following: i) describing the expression pattern 
of the Hippo transducers TAZ/YAP, ii) providing hints on 
their functional status by assessing CTGF as a readout 
for their activation, iii) providing information on their 
association with histological and molecular features (e.g. 
histotype, tumor grade, nodal status, hormone receptors, 
Ki-67), and iv) analyzing the impact of their expression on 
overall survival. 
RESULTS
For this study, 255 MBC patients were screened for 
the expression of TAZ, YAP and CTGF in their tumors. 
Upon molecular analyses, 129 patients were considered 
eligible (Figure 1). Baseline characteristics of these 
patients are summarized in Table 1. Representative 
immunohistochemical staining patterns are illustrated in 
Supplementary Figure 1.
We observed a positive association between TAZ 
and YAP and between TAZ and CTGF, and a suggestion 
for an association between YAP and CTGF (TAZ and YAP 
p < 0.001; TAZ and CTGF p < 0.001; YAP and CTGF 
p = 0.073, Figure 2, panel A). Moreover, a significant 
correlation between TAZ and CTGF and YAP and CTGF 
was seen in terms of tumor-expressing cells (Figure 2, 
panel B). On this basis, samples were considered to have 
active TAZ/YAP-driven gene transcription when they co-
expressed TAZ and CTGF (TAZ/CTGF) or YAP and CTGF 
(YAP/CTGF). 
We did not observe any significant association 
between the TAZ/CTGF and YAP/CTGF phenotypes and 
clinical-molecular features (Supplementary Table 1). At 
a median follow-up of 183 months, 37 deaths occurred. 
Patients with TAZ/CTGF and YAP/CTGF tumors had 
significant poorer overall survival compared with their 
negative counterparts (log rank p = 0.036 for both, Figure 3), 
and comparable results were obtained when considering 
triple-positive tumors (TAZ/YAP/CTGF, log rank p = 0.036, 
data available upon request). These findings were further 
confirmed when analyzing the 108 patients with invasive 
ductal carcinoma (IDC) or invasive lobular carcinoma 
(ILC) (log rank p = 0.013 and p = 0.011 for TAZ/CTGF and 
YAP/CTGF, respectively, as shown in Figure 4). 
In subgroup analyses, the TAZ/CTGF and YAP/
CTGF phenotypes were associated with an increased risk of 
death also in patients with ER+/PgR+ tumors, G3 tumors, 
and tumors with elevated Ki-67 levels (≥ 14) (Figure 5).  
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Multivariate Cox regression models, presented in 
Table 2, confirmed that patients with TAZ/CTGF and 
YAP/CTGF tumors were at increased risk of death (HR 
2.03, 95% CI: 1.06–3.90, p = 0.033; and HR 2.00, 95% 
CI: 1.04–3.84, p = 0.037, respectively). This association 
was maintained even when adjusting by clinical-molecular 
variables that did not test significant at the univariate 
assessment (TAZ/CTGF: HR 2.10, 95% CI: 1.08–4.07, 
p = 0.028. YAP/CTGF: HR 2.10, 95% CI: 1.07–4.09, 
p = 0.030, Table 2). In a sensitivity analysis carried out by 
excluding uncommon histotypes (N = 21), TAZ/CTGF and 
YAP/CTGF were the only variables that tested significant 
in multivariate Cox regression models (HR 2.34, 95% CI: 
1.16–4.73, p = 0.018, and HR 2.36, 95% CI: 1.17–4.77, 
p = 0.017, respectively, Table 3). Finally, nearly comparable 
results were obtained in the subpopulation of MBC patients 
with available nodal status (N = 92) (Supplementary 
Table 2). 
DISCUSSION 
In this study, we investigated the expression of 
key components of the Hippo transcriptional module in 
a large cohort of MBC patients with available survival 
data. Our results suggest that MBC patients whose tumors 
co-express TAZ, or YAP, and CTGF may have inferior 
survival compared with their negative counterparts. To 
our knowledge, this is the first study pointing to the Hippo 
pathway in MBC. Even though our results are hypothesis-
generating, we were able to apply preclinical information 
related to an emerging oncogenic avenue to a rare disease 
such as MBC, and with a clear focus on clinical outcomes. 
We acknowledge that our results should be viewed 
with caution in consideration of the retrospective nature of 
this study. Moreover, some potential limitations deserve 
mention. First, despite our best efforts, we were unable 
to gather all the necessary information related to systemic 
anticancer treatments. Second, in this series 37 events were 
recorded. Fourteen events were MBC-related deaths, but we 
ignore the cause of the remaining 23 deaths (62% of the 
total). This hindered the analysis of cancer specific mortality 
in an elderly patient population. Unfortunately, we are 
unable to address this issue. However, the TAZ/CTGF and 
YAP/CTGF phenotypes were predictive of overall survival 
in: i) patients whose tumors displayed aggressive molecular 
features (i.e. high grade and elevated Ki-67 levels), and ii) 
Figure 1: Flow diagram of the patients’ selection process.
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patients with the most common form of MBC (i.e. ER+ 
and PgR+ tumors, IDC). These characteristics delineate the 
prototype of MBC patients who usually receive adjuvant 
therapy, and eventually will experience disease recurrence. 
Consistently, patients with TAZ/CTGF- and YAP/CTGF-
positive tumors had significant shorter disease-free survival 
(DFS) compared with their negative counterparts (log 
rank p = 0.038 and p = 0.046, respectively, reported in 
Supplementary Figure 2), even though missing information 
pertinent to the events considered in the definition of DFS 
(local recurrence, distant recurrence, death from any cause) 
needs to be considered. More importantly, multivariate Cox 
regression models suggested that the TAZ/CTGF and YAP/
CTGF variables were independent predictors of survival. 
Despite these limitations, our study provided some 
intriguing clues. We have already discussed some strategies 
for interpreting TAZ/YAP expression [21]. Nuclear 
localization is often considered as a proxy of TAZ/YAP 
activation. Nevertheless, TAZ/YAP activity supposedly 
oscillates over time depending on specific tissue contexts 
[22]. Different observations account for that. First, somatic 
mutations in Hippo pathway components potentially 
leading to TAZ/YAP constitutional activity are uncommon 
[21]. For instance, neurofibromin 2 (NF2, also known as 
Table 1: Baseline characteristics of the study participants (N = 129)
Characteristics N (%)
Age at diagnosis*
 Median (min-max) [IQ range] 67.5 (34–88) [59–75]
Histology
 IDC/ILC 108 (83.7)
 Other   21 (16.3)
Grade
 G1-2  67 (51.9)
 G3  62 (48.1)
Nodal status
 Negative  39 (30.2)
 Positive  53 (41.1)
 Unknown  37 (28.7)
Hormone receptors
 ER+/PgR+ 109 (84.5)
 Other   20 (15.5)
Ki-67
 Low (< 14%)  73 (56.6)
 High (≥ 14%)  56 (43.4)
TAZ
 0 44 (34.1)
 Cytoplasm 56 (43.4)
 Nucleus 3 (2.3)
 Nucleus/Cytoplasm 26 (20.2)
YAP
 0 13 (10.1)
 Cytoplasm 98 (76.0)
 Nucleus 0 (0.0)
 Nucleus/Cytoplasm 18 (14.0)
CTGF
 Neg 77 (59.7)
 Pos 52 (40.3)
*computed in 108 patients. 
Abbreviations: IDC: invasive ductal carcinoma, ILC: invasive lobular carcinoma.
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Figure 2: Relationship between TAZ, YAP and CTGF. Association (OncoPrints in panel A) and correlation (panel B) between 
TAZ, YAP and CTGF in 129 male breast cancer samples.
Figure 3: Kaplan-Meier survival curves of overall survival regarding. (A) TAZ/CTGF and (B) YAP/CTGF in the entire study 
population (N = 129).
Figure 4: Kaplan-Meier survival curves of overall survival regarding. (A) TAZ/CTGF and (B) YAP/CTGF in patients with 
IDC/ILC (N = 108).
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Merlin), which is known to be mutationally inactivated 
in some cancers [32], is rarely mutated in FBC [37] and 
initial genetic characterization of MBC did not unveil 
any alteration in core Hippo pathway components [38]. 
Thus, defective control of TAZ/YAP is probably driven by 
functional cues, rather than by genetic events. This is not 
surprising when considering the nature of key regulatory 
branches controlling their nuclear shuttling, such as cell-
cell adhesion mechanisms, apical-basal polarity factors, 
and mechanical forces (mechanotransduction) imposed 
on cancer cells by the extracellular matrix (ECM) and cell 
density [34, 39–41]. These stimuli feed TAZ/YAP activation 
in a context-dependent manner on the basis, for instance, 
of the topographic localization of cells within a tumor. The 
same considerations can be extended to hypoxic regions, 
when considering the reciprocal interaction between 
hypoxia-inducible factor 1 (HIF-1) and TAZ in BCSC 
models [42, 43]. Second, TAZ/YAP require the interaction 
with other factors, including TEAD, SMAD and RUNX 
proteins, for promoting the transcription of target genes. 
Defective interaction with, or activity of, these partners 
hampers gene transcription independently on whether TAZ/
YAP localize to the nucleus [44]. Seminal evidence reported 
frequent RUNX1 deletions and MLL3 mutations in MBC 
Figure 5: Forest plots for subgroup analysis of overall survival (TAZ/CTGF and YAP/CTGF models).
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Table 2: Univariate and multivariate Cox regression models of disease-related features and overall 
survival (N = 129)
Univariate Cox Multivariate Cox
Regression model Regression model§ Regression model#
HR  
(95% CI)
p-value HR  
(95% CI)
p-value HR  
(95% CI)
p-value HR  
(95% CI)
p-value HR  
(95% CI)
p-value
Histology
IDC/
ILC vs 
other
1.20 
(0.47–3.08)
0.709
1.12 
(0.42–
2.99)
0.817
1.13 
(0.42–
3.00)
0.810
Grade G3 vs 
G1-2
2.01 
(1,03–3.93)
0.042
2.06 
(1.05–
4.05)
0.035
2.04 
(1.04–
4.00)
0.039
1.93 
(0.94–
3.93)
0.072
1.89 
(0.92–
3.85)
0.081
Hormone 
receptors
ER+/
PgR+ 
vs 
other
0.77 
(0.35–1.70)
0.516
0.80 
(0.36–
1.78)
0.578
0.79 
(0.35–
1.78)
0.571
Ki-67 High 
vs Low
1.16 
(0.61–2.24)
0.651
1.13 
(0.58–
2.24)
0.072
1.18 
(0.60–
2.34)
0.637
TAZ/
CTGF
TAZ/
CTGF 
vs 
other
1.98 
(1.03–3.78)
0.040
2.03 
(1.06–
3.90)
0.033
2.10 
(1.08–
4.07)
0.028
YAP/
CTGF
YAP/
CTGF 
vs 
other
1.97 
(1.03–3.77)
0.040
2.00 
(1.04–
3.84)
0.037
2.10 
(1.07–
4.09)
0.030
§Backward stepwise exclusion. # Adjusted for: Histology, Grade, Hormone receptor status, and  Ki-67. 
Table 3: Univariate and multivariate Cox regression models of disease-related features and overall 
survival in MBC patients with  IDC/ILC (N = 108)
Univariate Cox Multivariate Cox
Regression model Regression model§ Regression model#
HR  
(95% CI)
p-value HR  
(95% CI)
p-value HR  
(95% CI)
p-value HR  
(95% CI)
p-value HR  
(95% CI)
p-value
Grade G3 vs 
G1-2
1.98 
(0.95–
4.14)
0.069
1.96 
(0.94–
4.09)
0.075
1.92 
(0.92–
4.03)
0.082
1.82 
(0.84–
3.94)
0.132
1.76 
(0.81–
3.84)
0.154
Hormone 
receptors
ER+/
PgR+ vs 
other
0.63 
(0.28–
1.42)
0.266
0.66 
(0.28–
1.53)
0.328
0.65 
(0.28–
1.53)
0.327
Ki-67 High vs 
Low
1.00 
(0.49–
2.03)
0.998
1.03 
(0.49–
2.17)
0.937
1.09 
(0.51–
2.31)
0.825
TAZ/
CTGF
TAZ/
CTGF 
vs other
2.36 
(1.17–
4.76)
0.016
2.34 
(1.16–
4.73)
0.018
2–40 
(1.18–
4.90)
0.016
YAP/
CTGF
YAP/
CTGF 
vs other
2.41 
(1.20–
4.86)
0.014
2.36 
(1.17–
4.77)
0.017
2.44 
(1.18–
5.04)
0.016
§Backward stepwise exclusion. # Adjusted for: Histology, Grade, Hormone receptor status, and  Ki-67. 
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[38], and both these factors have been associated with TAZ/
YAP-mediated gene transcription [45, 46].  
To overcome this complexity, we decided to 
concomitantly analyze an established target of TAZ/
YAP. We chose CTGF for two reasons. First, CTGF is 
widely exploited for monitoring TAZ/YAP activation 
upon their forced overexpression, or knockout, in cellular 
models. Second, albeit TAZ and YAP are closely related 
proteins, the spectrum of up-regulated genes after their 
overexpression is partly different [47]. Nevertheless, 
CTGF ranked among top commonly up-regulated genes 
[47]. Based on this premise, and prompted by the co-
expression pattern, we opted for the TAZ/CTGF and YAP/
CTGF models for defining positive and negative cases. 
Next, in FBC activation of TAZ has been linked 
to BCSCs through a multiplicity of mechanisms [33, 34, 
42, 43, 48, 49]. The first link between Hippo and BCSCs 
stemmed from the over-representation of a TAZ/YAP 
signature in G3 versus G1 tumors [34]. Consistently, 
poorly differentiated FBC are supposed to be enriched for 
CSCs [50]. We did not appreciate any clear association 
between TAZ/CTGF and YAP/CTGF phenotypes and 
tumor grade in the entire cohort. Nevertheless, when we 
exclusively considered G1 and G3 tumors, TAZ/CTGF 
and YAP/CTGF were significantly associated with poor 
differentiation (p = 0.006 and p = 0.002, respectively, data 
available upon request). Moreover, in subgroup analysis, 
the expression of TAZ/CTGF and YAP/CTGF conferred 
poorer overall survival in patients with G3 tumors, but 
not in those with G1-2 tumors. In the entire population 
(N = 129), higher tumor grade seemed to be also associated 
with shorter survival, and this is consistent with an 
independent study that analyzed survival outcomes of 
~3.000 MBC patients [51]. A plausible hypothesis is that 
TAZ/YAP activity may be also necessary for maintenance/
amplification of the CSC compartment in MBC. Considering 
the unavailability of MBC cellular models for preclinical 
studies and the growing interest surrounding CSC-related 
biomarkers for predicting therapeutic outcomes, we are 
striving to establish MBC patient-derived tumor-initiating 
cells for functional characterization and mechanistic studies.
Another aspect that deserves mention refers to the 
metabolic control of TAZ/YAP and its connection with 
hormone receptor pathways. As aforementioned, a variety 
of stimuli that either encourage or restrain TAZ/YAP activity 
intersect the Hippo cascade. The mevalonate pathway 
was recently described as an important regulator of TAZ/
YAP [52]. Geranylgeranyl pyrophosphate produced in 
the mevalonate cascade is required for correct membrane 
tethering of Rho-GTPases which, in turn, act as positive 
regulators of TAZ/YAP. Consistently, inhibition of HMG-
CoA reductase, the rate-limiting enzyme of the mevalonate 
pathway, achieved with statins hindered the metabolic 
control of TAZ/YAP via altered prenylation of Rho 
GTPases [52]. Beyond protein prenylation, the mevalonate 
pathway is central for steroid and cholesterol biosynthesis. 
We hypothesized that HMG-CoA reductase may be a 
key intracellular node in MBC, and a nexus between 
TAZ/YAP and hormone receptors. Indeed, activation 
of the mevalonate cascade may influence the hormonal 
background that nourishes MBC cells, an hypothesis 
also supported by the link existing between obesity and 
MBC [3], while concomitantly activating TAZ/YAP via 
Rho GTPases. In the same cohort herein presented, we 
also carried out HMG-CoA reductase assessment. Our 
preliminary, still unpublished results indicate that HMG-
CoA reductase expression is positively associated with both 
hormone receptors and Hippo transducers. This allowed us 
to envision an oncogenic endocrine-metabolic background, 
possibly acting at both the systemic and local level, where 
the mevalonate pathway, endocrine stimuli and aberrant 
TAZ/YAP-driven gene transcription are tightly connected 
and cooperate in establishing an oncogenic network feeding 
MBC cells. Not surprisingly, recent preclinical evidence 
elucidated a positive estrogen-mediated control of TAZ/YAP 
operated by the G protein-coupled estrogen receptor (GPER) 
via the Gαq-11, PLCβ/PKC, and Rho/ROCK signaling 
pathways [53]. Based on the established association between 
obesity and MBC, along with the molecular data gathered 
on the plausible interconnection among the determinants 
of interest, e.g., Hippo transducers, mevalonate pathway 
and hormone receptors, we envision a role for statins in 
the treatment of MBC patients with specific molecular 
characteristics. To this end, observational studies evaluating 
the impact of statin use on survival outcomes, ideally upon 
assessment of specific markers suggestive of an endocrine-
metabolic-driven disease, are warranted.
Overall, our data suggested that the co-expression 
of the Hippo transducers TAZ/YAP and CTGF may be an 
adverse prognostic factor in MBC. Further research on this 
topic, envisioning a wider pathway analysis, is ongoing 
and will better delineate the contribution of altered Hippo 
signaling on MBC biology. 
MATERIALS AND METHODS 
Study participants and procedures 
For this retrospective study, samples from 255 
histologically confirmed MBC patients, previously 
characterized for common clinical-molecular features 
(histology, grade, hormone receptors, Ki-67) [7], were 
immunohistochemically analyzed for the expression 
of TAZ, YAP and CTGF. Patients did not receive any 
therapy before surgery. Adjuvant therapy mostly consisted 
in tamoxifen, but extensive data on systemic anticancer 
therapies were not available [7]. For this study, we applied 
the following eligibility criteria: i) complete data on TAZ, 
YAP and CTGF, and ii) availability of overall survival data. 
Of the 255 patients evaluated, 129 were considered eligible 
for this study. Nodal status was available for 92 patients. 
This subset of patients was separately analyzed. Overall 
survival (OS) was defined as the time from diagnosis until 
death from any cause.
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Tissue microarrays (TMAs) were built by using 
3 × 0.6 mm tissue cores per case obtained from formalin-
fixed paraffin-embedded (FFPE) material, as already 
detailed [7]. The immunohistochemical assessment of TAZ, 
YAP and CTGF was performed in FFPE tissues using the 
monoclonal antibody (MoAb) anti-TAZ (M2-616, BD 
Pharmingen, San Jose, CA,USA) at the dilution of 1:400, 
the MoAb anti-YAP (H-9, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) at the dilution of 1:200, and the polyclonal 
antibody anti-CTGF (HPA031074, Sigma-Aldrich, Saint 
Louis, MO) at the dilution of 1:50. 
TAZ, YAP and CTGF were graded on a four-grade 
scale (0: negative, 1+: weak, 2+: moderate, 3+: strong). TAZ 
and YAP were considered positive if ≥ 10% of neoplastic 
cells exhibited a distinct nuclear and/or cytoplasmic 
immunoreactivity of any intensity. CTGF was considered 
positive when ≥ 10% of neoplastic cells exhibited a distinct 
cytoplasmic immunoreactivity of any intensity. Two 
investigators (ADB and MM) blinded to treatment outcome 
evaluated immunoreactivity.
This retrospective study was conducted in accordance 
with the Declaration of Helsinki and approved by the 
Institutional Review Board of the “Regina Elena” National 
Cancer Institute of Rome, the coordinating centre, and 
by the Leeds (East) Research Ethics Committee (06/
Q1205/156). Informed consent was not required, as 
already specified [7]. The study adheres to the REporting 
recommendations for tumor MARKer prognostic studies 
(REMARK) criteria. 
Statistical analysis
Descriptive statistics were used to summarize the 
characteristics of the study participants. The relationship 
between categorical variables was assessed with the 
Pearson’s Chi-squared test of independence (2-tailed). The 
Fisher Exact test was used, when appropriate, depending 
upon the size of the groups compared. The Pearson’s 
correlation coefficient was used to investigate the correlation 
between TAZ, YAP and CTGF. The Kaplan-Meier method 
was used for estimating survival curves, which were 
compared by log-rank test. In order to identify independent 
predictors of survival, multivariate Cox proportional hazard 
models were built using stepwise regression (backward 
elimination). The related estimates were reported as Hazard 
Ratios (HR) and 95% Confident Interval (CI). Cox models 
were also generated by adjusting for clinical-molecular 
variables that may impact the investigated outcome. For the 
treatment of missing values (histology: 1/129, tumor grade: 
3/129, hormone receptors: 2/129, Ki-67 levels: 4/129), 
random hot deck (RHD) imputation was used [54]. Pools 
of potential donors were identified by matching for a set 
of auxiliary variables (histology, tumor grade, hormone 
receptor status and Ki-67, depending upon the nature of 
the missing variable). Afterwards, a donor was randomly 
selected and the value of interest assigned to the recipient. 
We considered statistically significant p values less than 
0.05. Statistical analyses were carried out using SPSS 
software (SPSS version 21, SPSS Inc., Chicago, IL, USA). 
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